M. Van Houdt , C. Kenis , S. Hatse , A. Laenen , M. Bergqvist , N.F. Ponde , L. Decoster , E. de Azambuja , C. Quaghebeur , F. Cornelis , D.M.E.C. Verhoeven , A. Barbeaux , V. Verschaeve , J. Mebis , P. Neven , H. Wildiers
{"title":"47P血清胸苷激酶活性在激素受体阳性和her2阴性的老年晚期乳腺癌患者接受核糖素和来曲唑治疗的RibOB试验","authors":"M. Van Houdt , C. Kenis , S. Hatse , A. Laenen , M. Bergqvist , N.F. Ponde , L. Decoster , E. de Azambuja , C. Quaghebeur , F. Cornelis , D.M.E.C. Verhoeven , A. Barbeaux , V. Verschaeve , J. Mebis , P. Neven , H. Wildiers","doi":"10.1016/j.esmoop.2025.104601","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104601"},"PeriodicalIF":7.1000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"47P Serum thymidine kinase activity in older patients with hormone receptor-positive and HER2-negative advanced breast cancer treated with ribociclib and letrozole in the RibOB trial\",\"authors\":\"M. Van Houdt , C. Kenis , S. Hatse , A. Laenen , M. Bergqvist , N.F. Ponde , L. Decoster , E. de Azambuja , C. Quaghebeur , F. Cornelis , D.M.E.C. Verhoeven , A. Barbeaux , V. Verschaeve , J. Mebis , P. Neven , H. Wildiers\",\"doi\":\"10.1016/j.esmoop.2025.104601\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11877,\"journal\":{\"name\":\"ESMO Open\",\"volume\":\"10 \",\"pages\":\"Article 104601\"},\"PeriodicalIF\":7.1000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ESMO Open\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2059702925004703\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Open","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2059702925004703","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
47P Serum thymidine kinase activity in older patients with hormone receptor-positive and HER2-negative advanced breast cancer treated with ribociclib and letrozole in the RibOB trial
期刊介绍:
ESMO Open is the online-only, open access journal of the European Society for Medical Oncology (ESMO). It is a peer-reviewed publication dedicated to sharing high-quality medical research and educational materials from various fields of oncology. The journal specifically focuses on showcasing innovative clinical and translational cancer research.
ESMO Open aims to publish a wide range of research articles covering all aspects of oncology, including experimental studies, translational research, diagnostic advancements, and therapeutic approaches. The content of the journal includes original research articles, insightful reviews, thought-provoking editorials, and correspondence. Moreover, the journal warmly welcomes the submission of phase I trials and meta-analyses. It also showcases reviews from significant ESMO conferences and meetings, as well as publishes important position statements on behalf of ESMO.
Overall, ESMO Open offers a platform for scientists, clinicians, and researchers in the field of oncology to share their valuable insights and contribute to advancing the understanding and treatment of cancer. The journal serves as a source of up-to-date information and fosters collaboration within the oncology community.